ライフサイエンスコーパス: major depression

1 brain bioenergetic function in subjects with major depression.

2 dically stable, unmedicated outpatients with major depression.

3 bit antidepressant activity in patients with major depression.

4 ve disorders including anxiety disorders and major depression.

5 en severe, can appear indistinguishable from major depression.

6 or only a small portion of burden related to major depression.

7 ificantly reduced in patients with psychotic major depression.

8 Randomization stratified for comorbid major depression.

9 DA) receptor antagonists in the treatment of major depression.

10 luence of the amygdala in chronic stress and major depression.

11 antidepressant effect in treatment-resistant major depression.

12 lts about its influence on disorders such as major depression.

13 ty and negative mood states in patients with major depression.

14 and structure may be a target biomarker for major depression.

15 bcortical increments in schizophrenia versus major depression.

16 across sexes in their impact on liability to major depression.

17 the pharmacologic treatment of patients with major depression.

18 adults from developing incident episodes of major depression.

19 lar disorder, and class III was increased in major depression.

20 ciated with psychiatric disorders, including major depression.

21 behaviors in animals that are homologous to major depression.

22 this will lead to new therapies for treating major depression.

23 be at either high or low risk for developing major depression.

24 predictors in treatment-naive patients with major depression.

25 control of sleep and play a critical role in major depression.

26 rily first-generation Mexican Americans with major depression.

27 of preschool conduct disorder in predicting major depression.

28 supporting an overlapping pathoetiology with major depression.

29 anial direct current stimulation (tDCS), for major depression.

30 sex differences in the etiologic pathways to major depression.

31 tudy on cortisol, cognition and psychosis in major depression.

32 mber of neuropsychiatric disorders including major depression.

33 r, 22.0% had bipolar disorder, and 12.0% had major depression.

34 id (GABA) concentrations in individuals with major depression.

35 their neural bases have been associated with major depression.

36 ailure with first-line treatment options for major depression.

37 e group of patients with treatment-resistant major depression.

38 nd parietal regions were more substantial in major depression.

39 mental role for NRG3 in bipolar disorder and major depression.

40 al and emotional impact of RPEs is intact in major depression.

41 ion is supposed to be a pathogenic factor in major depression.

42 ted with schizophrenia, bipolar disorder and major depression.

43 depressive symptoms, even in the absence of major depression.

44 ccelerated aging molecular profiles, such as major depression.

45 en severe, can appear indistinguishable from major depression.

46 th psoriasis met criteria for a diagnosis of major depression.

47 nonsignificant reduction in the incidence of major depression.

48 striatal dopaminergic indices in suicide and major depression.

49 the frontal pole as particularly altered in major depression.

50 represent the majority of those affected by major depression.

51 ty of psoriasis was unrelated to the risk of major depression.

52 ission with venlafaxine in older adults with major depression.

53 , regardless of severity, may be at risk for major depression.

54 it neurobiological underpinnings of risk for major depression.

55 polar disorder: -$148, 99.2% CI=-$217, -$85; major depression: -$100, 99.2% CI=-$123, -$77; adjustmen

56 zophrenia: 29%) than first-episode patients (major depression: 15%; schizophrenia: 12%).

57 e of hypertension (40% vs 23%; P = .013) and major depression (19% vs 6%; P = .005) was greater than

58 of an anxiety disorder (2.27, 1.2-4.28), and major depression (2.23, 1.24-4.01).

59 patients had higher misclassification rates (major depression: 23%; schizophrenia: 29%) than first-ep

60 yzed data from 80 older adults with remitted major depression (36 with mild cognitive impairment (LLD

61 he general population in Chile were seen for major depression (6.1% vs. 3.7% males, Z=2.58, p<0.05) a

62 itional voucher group had decreased rates of major depression (6.5% vs 10.9%; OR, 0.6 [95% CI, 0.3-0.

63 r group had significantly increased rates of major depression (7.1% vs 3.5%; odds ratio (OR), 2.2 [95

64 ed to identify white matter abnormalities in major depression (736 patients vs. 668 control subjects)

65 s have demonstrated HPA axis overactivity in major depression, a relationship of HPA axis activity to

66 ationship between childhood maltreatment and major depression according to 5-HTTLPR genotype.

67 e established evidence for Hb involvement in major depression, addiction, and schizophrenia, as well

68 139 outpatients with persistent symptoms of major depression after an 8-week open-label trial of esc

69 They often co-occur with major depression, alcohol and other substance-use disord

70 ) cases of psoriasis and 968 (7.8%) cases of major depression among 12,382 US citizens included in ou

71 Eighty medication-free outpatients with major depression and 34 matched healthy controls were in

72 In a recent trial for comorbid major depression and alcohol dependence, combination tre

73 utamatergic system in the pathophysiology of major depression and also as a target for rapid-acting a

74 ern, seen in the internalizing conditions of major depression and anxiety disorders, risk was associa

75 a risk factor for mental disorders, such as major depression and anxiety.

76 ing young children at highest risk for later major depression and applying early interventions.

77 to schizophrenia, autism, bipolar disorder, major depression and attention deficit hyperactivity dis

78 Major depression and bipolar disorder are characterized

79 Major depression and bipolar disorder are heterogeneous

80 ructure differences and similarities between major depression and bipolar disorder is a necessary ste

81 74 older individuals (age >/= 65 years) with major depression and cognitive impairment to the level o

82 to address the unmet needs of patients with major depression and even shorter life expectancy.

83 scitalopram and duloxetine) in patients with major depression and examined the moderating effect of p

84 The only notable small difference was that major depression and generalized anxiety disorder dimens

85 ially involved in its therapeutic effects on major depression and generalized anxiety disorder.

86 designed to evaluate the association between major depression and immune responses to a high-titer li

87 is substantially altered in individuals with major depression and is partially restored when depressi

88 sed interventions for preventing episodes of major depression and mitigating symptoms of depression.

89 ed across chronic brain conditions including major depression and normal aging.

90 tients with schizophrenia, bipolar disorder, major depression and normal controls (>700 subjects).

91 serotonergic system is often associated with major depression and obsessive compulsive disorder (OCD)

92 Moreover, people with major depression and other disorders often show effort-r

93 evelopment of new therapeutic strategies for major depression and other mood disorders.

94 idence already links circadian disruption to major depression and other mood disorders.

95 esion with 70% penetrance for schizophrenia, major depression and other psychiatric disorders in a Sc

96 risk for neuropsychiatric disorders such as major depression and post-traumatic stress disorder.

97 development of affective disorders including major depression and posttraumatic stress disorder.

98 ns of hippocampal and amygdala structures in major depression and predictors of ECT-related clinical

99 od maltreatment to modulate vulnerability to major depression and PTSD and epigenetic mechanisms thou

100 Many neurological diseases including major depression and schizophrenia manifest as dysfuncti

101 was correct in 80% and 72% of patients with major depression and schizophrenia, respectively, and in

102 mpact on the neuroanatomical separability of major depression and schizophrenia.

103 contributing to the comorbidity of CAD with major depression and schizophrenia.

104 y factors that moderate outcome in late-life major depression and that identify patients for whom ant

105 in 39 healthy participants, 39 patients with major depression, and 22 patients with major depression

106 including bipolar disease, schizophrenia and major depression, and a haplotype located in an intronic

107 r mental disorders, including schizophrenia, major depression, and bipolar disorders.

108 nduct disorder, drug abuse, prior history of major depression, and distal and dependent proximal stre

109 nfection and interferon-alpha, patients with major depression, and healthy controls).

110 ression significantly prevented the onset of major depression, and maintenance IPT significantly redu

111 t (HC-PFC) is associated with schizophrenia, major depression, and neurodegenerative disorders, and b

112 432 subjects PRS scores for plasma cortisol, major depression, and neuroticism were calculated using

113 , pairs discordant for a lifetime history of major depression, and pairs without either condition.

114 relatives of patients with bipolar disorder, major depression, and schizophrenia.

115 om dimensions shared among bipolar disorder, major depression, and schizophrenia.

116 lated and adjustment disorders; bereavement, major depression, and substance use disorders were also

117 ssociation between a stress-related disease, major depression, and the amount of mtDNA (p = 9.00 x 10

118 ia associated with autoimmune diseases, with major depression, and with unexplained chronic fatigue.

119 in 11 treatment-resistant older adults with major depression; and 33 matched historical controls.

120 e results suggest that important features of major depression are not captured by DSM criteria.

121 psoriasis was independently associated with major depression as assessed by a validated screening to

122 found, a simple family history assessment of major depression as part of clinical care can be a predi

123 critical relevance to the pathophysiology of major depression, as both subgenual hyperactivity and de

124 New cases of major depression, assessed every 6 months for 18 months.

125 previously reported a 90% decreased risk in major depression, assessed prospectively, in adult offsp

126 t 17% of humanity goes through an episode of major depression at some point in their lifetime.

127 n of parents who had documented histories of major depression (at-risk, n = 27; 8-14 years of age) an

128 Diagnosis of major depression based on the Patient Health Questionnai

129 rs (that is, bipolar, schizoaffective (SAF), major depression) based on contemporary diagnostic crite

130 treated hypothyroidism, Addison syndrome and major depression before treatment.

131 over the years to explain the development of major depression, bipolar disorder, and other mood disor

132 ase in risk for major psychiatric disorders (major depression, bipolar disorder, post-traumatic stres

133 licated in neuropsychiatric diseases such as major depression, bipolar disorder, schizophrenia, Alzhe

134 d past diagnoses of self-inflicted injuries, major depression, bipolar disorder, substance use disord

135 ms in schizophrenia or psychotic symptoms in major depression, but earlier disease onset and accelera

136 20% of adolescents experience an episode of major depression by age 18 years yet few receive evidenc

137 r antidepressant medication for nonpsychotic major depression can be extended to treatment-naive pati

138 Our findings suggest that major depression can be treated effectively in patients

139 ines how well DSM-5 symptomatic criteria for major depression capture the descriptions of clinical de

140 (PATH) is a treatment for older adults with major depression, cognitive impairment (from mild cognit

141 ion group (95% CI, 5.85% to 8.95%) developed major depression compared with 9.40% in the control (usu

142 sion in 143 older outpatients diagnosed with major depression comparing treatment response in three t

143 ric Genomics Consortium (PGC), the PGC2-MDD (Major Depression Dataset).

144 d to assess depressive symptoms and probable major depression (defined as Patient Health Questionnair

145 iority of behavioural activation therapy for major depression delivered via telemedicine to same-room

146 rter telomeres were seen in individuals with major depression, depressive disorders, and anxiety diso

147 showed that time to relapse or recurrence of major depression did not differ significantly between tr

148 psychiatry: Congestive Heart Failure (CHF), Major Depression Disorder (MDD), Parkinson's Disease (PD

149 seases, such as autism spectrum disorder and major depression, drawing upon findings from animal mode

150 d brain ageing promoted misclassification in major depression due to an increased neuroanatomical sch

151 -2.79; P < .001), and receiving a diagnosis (major depression/dysthymia: OR, 2.65; 95% CI, 2.20-3.20

152 generalized anxiety disorder, social phobia, major depression, dysthymic disorder, and/or minor depre

153 New episodes of major depression/dysthymic disorder (since baseline) wer

154 stionnaire in 331 employed participants with major depression enrolled in the Combining Medications t

155 to identify molecular mechanisms relevant to major depression, especially in the context of enhanced

156 Psoriasis was significantly associated with major depression, even after adjustment for sex, age, ra

157 Patients with treatment-resistant major depression experiencing a major depressive episode

158 asidone in adults with nonpsychotic unipolar major depression experiencing persistent symptoms after

159 e more important in the etiologic pathway to major depression for men.

160 ing need exists to improve the management of major depression for patients attending specialist cance

161 diovascular event did not modify the risk of major depression for patients with psoriasis.

162 ionships played a stronger etiologic role in major depression for women than for men.

163 onal Neuropsychiatric Interview criteria for major depression from an urban HIV care centre in Kitgum

164 We enrolled outpatients with major depression from three cancer centres and their ass

165 We enrolled patients with lung cancer and major depression from three cancer centres and their ass

166 digmatic cases involving alcohol dependence, major depression, general externalizing behaviors and an

167 Standardised scales measured major depression, generalised anxiety, alcohol misuse, a

168 m disorder, schizophrenia, bipolar disorder, major depression, generalized anxiety disorder, agorapho

169 t and youth informants for conduct disorder, major depression, generalized anxiety disorder, separati

170 nt and youth informants for conduct disorder,major depression, generalized anxiety disorder, separati

171 assigned 74% of the bipolar patients to the major depression group, while 83% of the first-episode p

172 who were 60 years of age or older and whose major depression had failed to remit with venlafaxine hy

173 The prevalence of major depression has increased in recent decades and wom

174 Notably, the rate of major depression has increased in recent decades, in par

175 rols (HCs) and patients with severe forms of major depression has not been well explored, but could e

176 mood and motivational disturbances, such as major depression, has been largely inferred from measure

177 Generalized anxiety and major depression have become increasingly common in the

178 Neuroimaging studies of patients with major depression have revealed abnormal intrinsic functi

179 isk for developing psychopathology including major depression in adulthood.

180 ation antidepressants for acute treatment of major depression in adults (update: Jan 8, 2016).

181 adolescence is the major period of onset for major depression in both risk groups, it is the offsprin

182 gulation of the stress axis is a hallmark of major depression in human patients.

183 oducible association of the SIRT1 locus with major depression in humans.

184 school-onset conduct disorder also predicted major depression in later childhood, but this associatio

185 risk factor for developing full criteria for major depression in later childhood, over and above othe

186 Major depression in older adults is common and can be ef

187 ess of an integrated treatment programme for major depression in patients with cancer (depression car

188 le with cancer is an effective treatment for major depression in patients with cancer.

189 acy of an integrated treatment programme for major depression in patients with lung cancer compared w

190 familial aggregation of bipolar disorder and major depression in the first nonclinical sample, and th

191 The increased rates of major depression in the high-risk group were largely acc

192 The increased risk of major depression in the offspring of depressed parents i

193 stpartum period appears to heighten risk for major depression in women.

194 The absolute prevalence of probable major depression increased by 7% after Occupy Central, r

195 site-specific permuted blocks stratified by major depression into groups prescribed CIT (n = 101), p

196 Major depression is a complex and severe psychiatric dis

197 Major depression is a psychiatric disorder with high pre

198 Major depression is an important complication of cancer.

199 Increasing clinical reports show that major depression is characterized by pronounced olfactor

200 Treatment-resistant major depression is common and potentially life-threaten

201 Major depression is common in patients attending cancer

202 Major depression is common in stroke patients and associ

203 elivered psychotherapy for older adults with major depression is not inferior to same-room treatment.

204 Major depression is the commonest psychiatric disorder a

205 with increased glutamate among patients with major depression is unknown.

206 Moreover, patients with comorbid major depression may fare better with IPT than with prol

207 data indicate that increased inflammation in major depression may lead to increased glutamate in the

208 cess in understanding the pathophysiology of major depression may result from excessive focus on the

209 oups: schizophrenia, bipolar disorder (BPD), major depression (MD) and unaffected controls.

210 Alcohol dependence (AD) and major depression (MD) are leading causes of disability t

211 patients admitted with acute schizophrenia, major depression (MD), and borderline personality disord

212 Past-year major depression (MD), generalized anxiety disorder (GAD

213 ronmental experiences contribute to risk for major depression (MD), we conducted joint autobiographic

214 p are the historical roots of our concept of major depression (MD)?

215 The degree to which major depression (MDD) and bipolar disorder (BD) are ass

216 gnosed with type 2 diabetes with and without major depression (MDD), a healthy control group, and a g

217 terature on reward processing dysfunction in major depression (MDD), bipolar disorder and schizophren

218 and was positively associated with past-year major depression (mean [SE], 100 [0.5]; P = .01).

219 cortical regions previously associated with major depression measured through T1-weighted magnetic r

220 f schizophrenia (n = 158) from patients with major depression (n = 104); and (ii) quantify the impact

221 la structures were examined in patients with major depression (N = 43, scanned three times: prior to

222 lities that inpatients with severe recurrent major depression (n = 465,646) were treated in a hospita

223 inded, noninferiority trial of patients with major depression (N=138; 63% female; age=56.7 years [SD=

224 es of patients with bipolar disorder (n=59), major depression (n=73), and schizophrenia (n=56) and 11

225 e diagnostic groups (healthy controls, n=17; major depression, n=38; and post-traumatic stress disord

226 dolescents (79% of those with a diagnosis of major depression; n = 023); most received psychotherapy

227 major depression (PMD) and with nonpsychotic major depression (NPMD) and healthy controls (HC) were s

228 ession (PMD); 26 patients with non-psychotic major depression (NPMD); and 29 HCs.

229 investigation in humans for the treatment of major depression, obsessive-compulsive disorder, and add

230 Comorbid major depression occurred in 36.7% (95% CI, 6.2%-67.2%)

231 Major depression occurs in 2% of adults aged 55 years or

232 r significant after controlling for maternal major depression (odds ratio (OR) 1.10 (0.70-1.70)).

233 yle factors, other risk factors for CHD, and major depression (odds ratio: 2.2; 95% confidence interv

234 of either a clinical sample of persons with major depression or a community control sample of person

235 vivors and examined whether they experienced major depression or anxiety disorders during that year a

236 ated with Lithium to patients diagnosed with Major Depression or Depressive Disorder who are treated

237 The first is with 48 patients diagnosed with Major Depression or Depressive Episode (average age = 49

238 r to three patient groups all diagnosed with Major Depression or Depressive Episode.

239 Health Questionnaire-9) and met criteria for major depression or dysthymia.

240 of which are covered by the DSM criteria for major depression or melancholia.

241 domestic violence, and those diagnosed with major depression or psychotic disorders were excluded.

242 whether these findings reflect the state of major depression or reflect trait neurobiological underp

243 ees diagnosed in 1999 with bipolar disorder, major depression, or adjustment disorder (N=19,094) and

244 Many older adults with major depression, particularly veterans, do not have acc

245 ) versus lateral (cognitive) frontal pole to major depression pathogenesis is currently unclear.

246 functionally connect to other key regions in major depression pathology, such as the anterior cingula

247 atients with major depression with psychotic major depression (PMD) and with nonpsychotic major depre

248 nts were studied: 40 patients with psychotic major depression (PMD); 26 patients with non-psychotic m

249 ess in individuals at high familial risk for major depression, possibly by expanding a cortical reser

250 tom of most psychiatric disorders, including major depression, post-traumatic stress disorder, schizo

251 DSM-IV symptom criteria for major depression; posttraumatic stress disorder; anxiety

252 ncrease was due to increases in the rates of major depression; posttraumatic stress disorder; other a

253 t reveal a synergistically increased risk of major depression (psoriasis and MI: OR, 1.09 [95% CI, 0.

254 ate-to-severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (

255 predictive model for treatment remission of major depression (receiver operating characteristic inte

256 Community adults with major depression, recurrent with seasonal pattern (N=177

257 The causes of major depression remain unknown.

258 atients with bipolar disorder have recurrent major depression, residual mood symptoms, and limited tr

259 s was not replicated in additional recurrent major depression samples (replication P=0.11).

260 ene coding for DISC1 clearly segregates with major depression, schizophrenia and related mental condi

261 People with major depression, schizophrenia, and Parkinson's disease

262 udes randomized controlled trials of tCS for major depression, schizophrenia, cognitive disorders, an

263 ne (score <16), minor (score 16 to <21), and major depression (score>/=21); and Center for Epidemiolo

264 Hospital Anxiety and Depression Scale; then, major depression section of the Structured Clinical Inte

265 The early onset of major depression seen in the offspring of depressed pare

266 Patients with major depression show reductions in striatal and paleost

267 ficit/hyperactivity disorder, schizophrenia, major depression, smoking, personality, cognition and bo

268 r who screened positive and met criteria for major depression, spoke English, and had telephone acces

269 status based on severity cutoff scores, and major depression status from tracking calls.

270 red in January or February of each year, and major depression status was assessed by telephone in Oct

271 hysiology of psychiatric diseases, including major depression, substance abuse, and schizophrenia.

272 For some highly prevalent disorders (major depression, substance abuse, anxiety disorders, an

273 This suggests that there could be a specific major depression subtype, inflammatory cytokine-associat

274 th major depression were at highest risk for major depression, suggesting the potential value of dete

275 stent with previously proposed typologies of major depression that suggest two subtypes that differ i

276 ts were 177 adults with a current episode of major depression that was recurrent with a seasonal patt

277 f symptoms are classically representative of major depression, the patient also raises themes regardi

278 dala reactivity is observed in patients with major depression, two critical gaps in our knowledge rem

279 60 years of age and met DSM-IV criteria for major depression underwent MRI and were enrolled in a 12

280 evaluate if AC3 is a contributing factor for major depression using mouse models lacking the Adcy3 ge

281 Diagnosis of offspring aged 18 years with major depression using the International Classification

282 The risk for major depression was approximately three times as high i

283 The prevalence of major depression was highest in patients with lung cance

284 ithin these cancer groupings, a diagnosis of major depression was more likely in patients who were yo

285 n adjusted multivariable models, the risk of major depression was not significantly different between

286 ng with 2 previous generations affected with major depression were at highest risk for major depressi

287 risk factors and the occurrence of past-year major depression were conducted at two waves of personal

288 f Chinese adults older than 60 years who had major depression were improved when their primary care c

289 Patients with comorbid major depression were nine times more likely than nondep

290 THOD: Adults aged 18-65 with treatment-naive major depression were randomly assigned with equal likel

291 ble-blind, crossover study, 20 patients with major depression were randomly assigned, and 18 complete

292 Youths 8-17 years of age with major depression were treated openly with fluoxetine for

293 on design study was conducted in adults with major depression who had an inadequate response to one o

294 otal of 60 medically stable outpatients with major depression who were either on a consistent antidep

295 but not unipolar major depressive disorder (major depression with no bipolarity; 18.9% compared with

296 bgenual cortex is disrupted in patients with major depression with psychotic features.

297 Patients with major depression with psychotic major depression (PMD) a

298 would be most apparent in patients that have major depression with psychotic symptoms, who typically

299 with major depression, and 22 patients with major depression with psychotic symptoms.

300 Medical conditions are often complicated by major depression, with consequent additional impairment